down arrow

Immunic, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4525EP1011
USD
0.69
0.04 (5.57%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.630.69

52 Week

0.561.39
Valuation
Technical
Day's Volume

CASH

1.06 M

Shareholding (Mar 2025)

FII

1.41%

Held by 19 FIIs

DII

88.62%

Held by 13 DIIs

Promoter

2.69%

How big is Immunic, Inc.?

22-Jun-2025

As of Jun 18, Immunic, Inc. has a market capitalization of 73.54 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -96.40 million over the latest four quarters. Shareholder's funds are 18.43 million, and total assets are 40.87 million as of Dec 24.

Market Cap: As of Jun 18, Immunic, Inc. has a market capitalization of 73.54 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Immunic, Inc. reported net sales of 0.00 million and a net profit of -96.40 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 18.43 million, while total assets were reported at 40.87 million.

Read More

What does Immunic, Inc. do?

22-Jun-2025

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. As of March 2025, it has a market cap of $73.54 million and reported a net profit of -$25 million.

Overview:<BR>Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for chronic inflammatory and autoimmune diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 73.54 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 2.56<BR>Return on Equity: 1,823.26%<BR>Price to Book: -13.91<BR><BR>Contact Details:<BR>Address: Am Klopferspitz 19, PLANEGG CA: 82152<BR>Tel: ['49 89 250079460', '49 892 08047709']<BR>Fax: 1 302 6555049

Read More

Who are in the management team of Immunic, Inc.?

22-Jun-2025

As of March 2022, the management team of Immunic, Inc. includes Dr. Daniel Vitt as President and CEO, along with independent directors Ms. Tamar Howson, Dr. Jorg Neermann, Dr. Vincent Ossipow, Mr. Barclay Phillips, and Mr. Jan Van den Bossche.

As of March 2022, the management team of Immunic, Inc. includes Dr. Daniel Vitt, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features several independent directors: Ms. Tamar Howson, Dr. Jorg Neermann, Dr. Vincent Ossipow, Mr. Barclay Phillips, and Mr. Jan Van den Bossche.

Read More

Is Immunic, Inc. technically bullish or bearish?

20-Sep-2025

As of July 17, 2025, Immunic, Inc. shows a mildly bearish technical trend with mixed indicators, underperforming the S&P 500 significantly over the past year.

As of 17 July 2025, the technical trend for Immunic, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The Bollinger Bands indicate a mildly bearish trend for both weekly and monthly periods. Daily moving averages are bearish, and the KST is mildly bullish on a weekly basis but bearish monthly. Dow Theory supports a mildly bullish outlook for both weekly and monthly periods, while the OBV is mildly bearish.<BR><BR>In terms of performance, Immunic has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -53.07% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a lack of strong bullish signals despite some mixed indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 82 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.61

stock-summary
Return on Equity

-300.30%

stock-summary
Price to Book

2.40

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-27 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.47%
0%
-14.47%
6 Months
-5.76%
0%
-5.76%
1 Year
-45.8%
0%
-45.8%
2 Years
-42.64%
0%
-42.64%
3 Years
-49.39%
0%
-49.39%
4 Years
-91.73%
0%
-91.73%
5 Years
-96.17%
0%
-96.17%

Immunic, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Immunic, Inc. technically bullish or bearish?

As of 17 July 2025, the technical trend for Immunic, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The Bollinger Bands indicate a mildly bearish trend for both weekly and monthly periods. Daily moving averages are bearish, and the KST is mildly bullish on a weekly basis but bearish monthly. Dow Theory supports a mildly bullish outlook for both weekly and monthly periods, while the OBV is mildly bearish. In terms of performance, Immunic has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -53.07% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, reflecting a lack of strong bullish signals despite some mixed indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-193.83%
EBIT to Interest (avg)
-74.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.56
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
60.34%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-14.29
EV to EBIT
-0.61
EV to EBITDA
-0.61
EV to Capital Employed
-3.29
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (7.28%)

Foreign Institutions

Held by 19 Foreign Institutions (1.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -25.23% vs 10.83% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.00",
          "val2": "-22.80",
          "chgp": "-18.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.80",
          "val2": "-21.40",
          "chgp": "-25.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.37% vs 22.26% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-97.90",
          "val2": "-99.10",
          "chgp": "1.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-100.50",
          "val2": "-93.60",
          "chgp": "-7.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.00
-22.80
-18.42%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-26.80
-21.40
-25.23%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -25.23% vs 10.83% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-97.90
-99.10
1.21%
Interest
0.00
0.00
Exceptional Items
-4.80
0.00
Consolidate Net Profit
-100.50
-93.60
-7.37%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -7.37% vs 22.26% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Immunic, Inc. stock-summary
stock-summary
Immunic, Inc.
Pharmaceuticals & Biotechnology
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
Company Coordinates stock-summary
Company Details
Am Klopferspitz 19 , PLANEGG CA : 82152
stock-summary
Tel: 49 89 25007946049 892 08047709
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."